ENTRY       D00966                      Drug
NAME        Tamoxifen citrate (JP18/USP);
            Nolvadex (TN);
            Soltamox (TN)
PRODUCT     SOLTAMOX (Mayne Pharma)
  GENERIC   TAMOXIFEN CITRATE (A-S Medication Solutions)
            TAMOXIFEN CITRATE (Actavis Pharma)
            TAMOXIFEN CITRATE (Aurobindo Pharma Limited)
            TAMOXIFEN CITRATE (Golden State Medical Supply)
            TAMOXIFEN CITRATE (Mayne Pharma Commercial LLC)
            TAMOXIFEN CITRATE (McKesson Corporation dba SKY Packaging)
            TAMOXIFEN CITRATE (Mylan Pharmaceuticals)
            TAMOXIFEN CITRATE (NuCare Pharmaceuticals)
            TAMOXIFEN CITRATE (NuCare Pharmaceuticals)
            TAMOXIFEN CITRATE (Proficient Rx LP)
            TAMOXIFEN CITRATE (Zydus Lifesciences Limited)
            TAMOXIFEN CITRATE (Zydus Pharmaceuticals USA)
FORMULA     C26H29NO. C6H8O7
EXACT_MASS  563.2519
MOL_WEIGHT  563.6381
CLASS       Antineoplastic
             DG01585  Estrogen receptor antagonist
              DG01620  Tamoxifene-type antineoplastic
            Hormonal agent
             DG01619  Estrogen receptor antagonist/modulator
            Metabolizing enzyme substrate
             DG01644  CYP2D6 substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
REMARK      Therapeutic category: 4291
            ATC code: L02BA01
            Chemical structure group: DG00734
            Product (DG00734): D00966<JP/US>
EFFICACY    Antineoplastic, Estrogen receptor agonist/antagonist
  DISEASE   Breast cancer (ER-positive) [DS:H00031]
COMMENT     Active form of prodrug: Endoxifen [CPD:C16547]
TARGET      NR3A (ESR) [HSA:2099 2100] [KO:K08550 K08551]
  PATHWAY   hsa04915(2099+2100)  Estrogen signaling pathway
            hsa05200(2099+2100)  Pathways in cancer
            hsa05224(2099+2100)  Breast cancer
METABOLISM  Enzyme: CYP2D6 [HSA:1565], CYP3A4 [HSA:1576]
INTERACTION  
STR_MAP     map07043  Antineoplastics - hormones
            map07226  Progesterone, androgen and estrogen receptor agonists/antagonists
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L02 ENDOCRINE THERAPY
               L02B HORMONE ANTAGONISTS AND RELATED AGENTS
                L02BA Anti-estrogens
                 L02BA01 Tamoxifen
                  D00966  Tamoxifen citrate (JP18/USP) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Antiestrogens/Modifiers
               Tamoxifen
                D00966  Tamoxifen citrate (JP18/USP)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D00966  Tamoxifen citrate (JP18/USP)
            Drug groups [BR:br08330]
             Antineoplastic
              DG01585  Estrogen receptor antagonist
               DG01620  Tamoxifene-type antineoplastic
                DG00734  Tamoxifen
                 D00966  Tamoxifen citrate
             Hormonal agent
              DG01619  Estrogen receptor antagonist/modulator
               DG00734  Tamoxifen
                D00966  Tamoxifen citrate
             Metabolizing enzyme substrate
              DG01644  CYP2D6 substrate
               DG00734  Tamoxifen
                D00966  Tamoxifen citrate
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                DG00734  Tamoxifen
                 D00966  Tamoxifen citrate
            Drug classes [BR:br08332]
             Antineoplastic
              DG01585  Estrogen receptor antagonist
               D00966  Tamoxifen citrate
            Target-based classification of drugs [BR:br08310]
             Nuclear receptors
              Estrogen like receptors
               Estrogen receptor
                NR3A (ESR)
                 D00966  Tamoxifen citrate (JP18/USP) &lt;JP/US&gt;
            Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
             Chemicals
              D00966  Tamoxifen citrate
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D00966
            Pharmacogenomic biomarkers [br08341.html]
             Somatic variations in targeted cancer therapies
              D00966
            Drug groups [BR:br08330]
             Antineoplastic
              DG01585  Estrogen receptor antagonist
               DG01620  Tamoxifene-type antineoplastic
                DG00734  Tamoxifen
             Hormonal agent
              DG01619  Estrogen receptor antagonist/modulator
               DG00734  Tamoxifen
             Metabolizing enzyme substrate
              DG01644  CYP2D6 substrate
               DG00734  Tamoxifen
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                DG00734  Tamoxifen
            Prodrugs [br08324.html(DG00734)]
             DG00734
DBLINKS     CAS: 54965-24-1
            PubChem: 7848029
            ChEBI: 9397
            LigandBox: D00966
            NIKKAJI: J327.784D
ATOM        41
            1   C1d C    44.5200  -20.0900
            2   C1b C    43.3300  -20.7900
            3   C1b C    45.7100  -20.7900
            4   C6a C    45.2200  -18.9000
            5   O1a O    43.8200  -18.9000
            6   C6a C    42.0700  -20.0900
            7   C6a C    45.7100  -22.1900
            8   O6a O    44.5200  -17.6400
            9   O6a O    46.6200  -18.9000
            10  O6a O    40.8800  -20.7900
            11  O6a O    42.0700  -18.6900
            12  O6a O    46.9700  -22.8900
            13  O6a O    44.5200  -22.8900
            14  C8x C    32.8300  -21.0700
            15  C8y C    32.8300  -22.4700
            16  C8x C    31.6400  -23.1700
            17  C8x C    30.3800  -22.4700
            18  C8y C    30.3800  -21.0700
            19  C8x C    31.6400  -20.3700
            20  C8x C    27.9300  -22.4700
            21  C8y C    27.9300  -21.0700
            22  C2c C    29.1900  -20.3700
            23  C8x C    26.7400  -23.1700
            24  C8x C    25.5500  -22.4700
            25  C8x C    25.5500  -21.0700
            26  C8x C    26.7400  -20.3700
            27  C2c C    29.1900  -18.9700
            28  C1b C    27.9300  -18.2700
            29  C8y C    30.3800  -18.2700
            30  O2a O    34.0200  -23.1700
            31  C1b C    35.2100  -22.4700
            32  C1b C    36.4000  -23.1700
            33  C8x C    30.3800  -16.8700
            34  C8x C    31.5700  -16.1700
            35  C8x C    32.8300  -16.8700
            36  C8x C    32.8300  -18.2700
            37  C8x C    31.5700  -18.9700
            38  N1c N    37.5900  -22.4700
            39  C1a C    38.7800  -23.1700
            40  C1a C    37.5900  -21.0700
            41  C1a C    26.7400  -18.9700
BOND        42
            1     1   2 1
            2     1   3 1
            3     1   4 1
            4     1   5 1
            5     2   6 1
            6     3   7 1
            7     4   8 1
            8     4   9 2
            9     6  10 1
            10    6  11 2
            11    7  12 1
            12    7  13 2
            13   14  15 2
            14   15  16 1
            15   16  17 2
            16   17  18 1
            17   18  19 2
            18   14  19 1
            19   20  21 1
            20   21  22 1
            21   18  22 1
            22   20  23 2
            23   23  24 1
            24   24  25 2
            25   25  26 1
            26   21  26 2
            27   22  27 2
            28   27  28 1
            29   27  29 1
            30   15  30 1
            31   30  31 1
            32   31  32 1
            33   29  33 2
            34   33  34 1
            35   34  35 2
            36   35  36 1
            37   36  37 2
            38   29  37 1
            39   32  38 1
            40   38  39 1
            41   38  40 1
            42   28  41 1
///
